Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12Tip Ranks·Jul 27 at 12:35 PMKAPA+0.30%BAYRY+2.42%
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer | KAPA Stock NewsStockTitan·Jul 21 at 11:35 PMKAPA+0.30%BAYRY+2.42%
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga_article·Jul 17 at 07:05 AMLIMN-3.50%RGNX+5.20%
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLCWorldPharmaceuticals·Jul 16 at 04:46 AMKAPA+0.30%
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?benzinga_article·Jul 16 at 01:51 AMKAPA+0.30%
Kairos Pharma reports interim Phase 1 safety data for ENV-105 with Tagrisso in EGFR-mutated lung cancerPUBT·Jul 15 at 07:32 AMKAPA+0.30%AZN-1.13%
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | KAPA Stock NewsStockTitan·Jul 14 at 11:39 PMKAPA+0.30%
Kairos Pharma Shareholders Approve Reverse Split, Governance MeasuresTip Ranks·Jun 30 at 04:50 PMKAPA+0.30%
Kairos Pharma holds annual shareholder meeting, approves reverse stock split authorizationPUBT·Jun 30 at 04:20 PMKAPA+0.30%
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to ShareholdersFidelity·Jun 4 at 07:00 AMKAPA+0.30%
